Buffett boosts his Japanese trading house holdings to around 9%
warrenbuffet

Billionaire investor Warren Buffett’s Berkshire Hathaway has raised its stake in Japan’s top five trading firms to around 9%, it said in its annual report.

Berkshire Hathaway’s wholly owned subsidiary National Indemnity Company previously held about 7% to 8% in Mitsubishi, Itochu, Mitsui & Co., Sumitomo and Marubeni, according to filings made in June.

Berkshire first announced its stakes in the trading houses in 2020 with the intention of holding them long-term and increasing them to as much as 9.9%.

Berkshire Hathaway said in the report, dated Feb. 24, that it paid ¥1.6 trillion ($10.63 billion) for the five stakes, which were valued at ¥2.9 trillion at the end of 2023. In dollar terms, that translated to unrealized gains of 61% or $8 billion, it said.

Source: The Japan Times

Related Articles

General
Information, News
The government’s current wood utilization strategy targets buildings with up to three stories, but it will expand the coverage to structures with four or more stories in response to technological innovation, the sources said.
General, Investors/Business
Information, News
Japan Post Bank amplifies its real estate holdings to $27 billion, marking a significant 17.6% uptick from last year. Their strategic global diversification, notably in North America and Europe, mirrors a broader trend of Japanese investors exploring overseas markets in the post-Covid era.
Investors/Business, General
Information, News
Tokyo's office market faced challenges during the pandemic, experiencing reduced foot traffic and increased vacancies. To adapt to shifting tenant needs and diversify income, upcoming developments are increasingly incorporating mixed-use elements. Projects like Tokyo Torch and Jingu Gaien reflect this trend, integrating sustainability and community amenities to attract and retain talent in Japan's competitive labor market.
General
Information, News
Japan's Ajinomoto is set to acquire U.S.-based Forge Biologics for $546 million. The deal, pending regulatory approval, is expected to be completed in December 2023. Ajinomoto plans to integrate Forge into its AminoScience platform to advance treatments for rare diseases.